# Aprea Therapeutics, Inc.: financial statements, quarterly

APRE · Nasdaq · CIK 1781983 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/apre.md) · [Financials](/companies/apre/financials.md) · [Filings](/companies/apre/filings.md) · [Insiders](/companies/apre/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/apre/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,523)](/filings/0001558370-24-014767.md) | [(3,675) d](/filings/0001558370-25-003588.md) | [(3,150)](/filings/0001558370-25-007667.md) | [(3,847)](/filings/0001558370-25-011152.md) | [(4,097)](/filings/0001104659-25-109867.md) | [(3,226) d](/filings/0001104659-26-028068.md) | [(4,086)](/filings/0001104659-26-059743.md) | [(3,388)](/filings/0001104659-26-094544.md) | [(3,117)](/filings/0001104659-25-109867.md) | [(2,643) d](/filings/0001104659-26-028068.md) | [(3,430)](/filings/0001104659-26-059743.md) | [(4,032)](/filings/0001104659-26-094544.md) |
| Income tax | $k | [0.0](/filings/0001558370-24-014767.md) | [0.0 d](/filings/0001558370-25-003588.md) | [0.0](/filings/0001558370-25-007667.md) | [0.0](/filings/0001558370-25-011152.md) | [0.0](/filings/0001104659-25-109867.md) | [0.0 d](/filings/0001104659-26-028068.md) | [0.0](/filings/0001104659-26-059743.md) | [0.0](/filings/0001104659-26-094544.md) | [0.0](/filings/0001104659-25-109867.md) | [0.0 d](/filings/0001104659-26-028068.md) | [0.0](/filings/0001104659-26-059743.md) | [0.0](/filings/0001104659-26-094544.md) |
| Net income | $k | [(3,205)](/filings/0001558370-24-014767.md) | [(3,443) d](/filings/0001558370-25-003588.md) | [(2,810)](/filings/0001104659-25-109867.md) | [(3,470)](/filings/0001104659-25-109867.md) | [(3,784)](/filings/0001104659-25-109867.md) | [(2,895) d](/filings/0001104659-26-028068.md) | [(3,933)](/filings/0001104659-26-094544.md) | [(3,239)](/filings/0001104659-26-094544.md) | [(2,972)](/filings/0001104659-25-109867.md) | [(2,456) d](/filings/0001104659-26-028068.md) | [(3,288)](/filings/0001104659-26-094544.md) | [(3,591)](/filings/0001104659-26-094544.md) |
| Diluted EPS | $ per share | [(0.86)](/filings/0001558370-24-014767.md) | not reported | [(0.67)](/filings/0001558370-25-007667.md) | [(0.58)](/filings/0001558370-25-011152.md) | [(0.64)](/filings/0001104659-25-109867.md) | not reported | [(0.66)](/filings/0001104659-26-059743.md) | [(0.53)](/filings/0001104659-26-094544.md) | [(0.47)](/filings/0001104659-25-109867.md) | not reported | [(0.22)](/filings/0001104659-26-059743.md) | [(0.07)](/filings/0001104659-26-094544.md) |
| Basic EPS | $ per share | [(0.86)](/filings/0001558370-24-014767.md) | not reported | [(0.67)](/filings/0001558370-25-007667.md) | [(0.58)](/filings/0001558370-25-011152.md) | [(0.64)](/filings/0001104659-25-109867.md) | not reported | [(0.66)](/filings/0001104659-26-059743.md) | [(0.53)](/filings/0001104659-26-094544.md) | [(0.47)](/filings/0001104659-25-109867.md) | not reported | [(0.22)](/filings/0001104659-26-059743.md) | [(0.07)](/filings/0001104659-26-094544.md) |

- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.4](/filings/0001558370-24-014767.md) | [21.6](/filings/0001558370-25-003588.md) | [32.4](/filings/0001558370-25-007667.md) | [28.7](/filings/0001558370-25-011152.md) | [26.2](/filings/0001104659-25-109867.md) | [22.8](/filings/0001104659-26-028068.md) | [19.3](/filings/0001104659-26-059743.md) | [16.5](/filings/0001104659-26-094544.md) | [13.7](/filings/0001104659-25-109867.md) | [14.6](/filings/0001104659-26-094544.md) | [46.5](/filings/0001104659-26-059743.md) | [41.2](/filings/0001104659-26-094544.md) |
| Current assets | $m | [25.6](/filings/0001558370-23-018572.md) | [22.5](/filings/0001558370-25-003588.md) | [33.1](/filings/0001558370-24-008069.md) | [29.6](/filings/0001558370-24-011806.md) | [26.5](/filings/0001558370-24-014767.md) | [23.6](/filings/0001104659-26-028068.md) | [19.8](/filings/0001558370-25-007667.md) | [16.9](/filings/0001558370-25-011152.md) | [13.9](/filings/0001104659-25-109867.md) | [15.6](/filings/0001104659-26-094544.md) | [47.2](/filings/0001104659-26-059743.md) | [41.9](/filings/0001104659-26-094544.md) |
| Total assets | $m | [25.8](/filings/0001558370-23-018572.md) | [22.7](/filings/0001558370-25-003588.md) | [33.2](/filings/0001558370-24-008069.md) | [30.0](/filings/0001558370-24-011806.md) | [26.9](/filings/0001558370-24-014767.md) | [24.0](/filings/0001104659-26-028068.md) | [20.2](/filings/0001558370-25-007667.md) | [17.3](/filings/0001558370-25-011152.md) | [14.3](/filings/0001104659-25-109867.md) | [15.9](/filings/0001104659-26-094544.md) | [47.6](/filings/0001104659-26-059743.md) | [42.3](/filings/0001104659-26-094544.md) |
| Current liabilities | $m | [4.2](/filings/0001558370-23-018572.md) | [4.4](/filings/0001558370-25-003588.md) | [3.0](/filings/0001558370-24-008069.md) | [3.1](/filings/0001558370-24-011806.md) | [3.6](/filings/0001558370-24-014767.md) | [3.4](/filings/0001104659-26-028068.md) | [3.4](/filings/0001558370-25-007667.md) | [3.2](/filings/0001558370-25-011152.md) | [2.7](/filings/0001104659-25-109867.md) | [2.8](/filings/0001104659-26-094544.md) | [5.3](/filings/0001104659-26-059743.md) | [3.1](/filings/0001104659-26-094544.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [20.3](/filings/0001558370-24-014767.md) | [17.0](/filings/0001104659-26-028068.md) | [28.9](/filings/0001104659-25-109867.md) | [25.6](/filings/0001104659-25-109867.md) | [21.9](/filings/0001104659-25-109867.md) | [19.3](/filings/0001104659-26-094544.md) | [15.5](/filings/0001104659-26-094544.md) | [13.4](/filings/0001104659-26-094544.md) | [10.9](/filings/0001104659-25-109867.md) | [12.4](/filings/0001104659-26-094544.md) | [41.6](/filings/0001104659-26-094544.md) | [38.5](/filings/0001104659-26-094544.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,242) d](/filings/0001558370-24-014767.md) | [(3,740) d](/filings/0001558370-25-003588.md) | [(3,936)](/filings/0001558370-25-007667.md) | [(3,642) d](/filings/0001558370-25-011152.md) | [(2,468) d](/filings/0001104659-25-109867.md) | [(3,511) d](/filings/0001104659-26-028068.md) | [(3,631)](/filings/0001104659-26-059743.md) | [(3,131) d](/filings/0001104659-26-094544.md) | [(3,171) d](/filings/0001104659-25-109867.md) | [(2,961) d](/filings/0001104659-26-028068.md) | [(2,757)](/filings/0001104659-26-059743.md) | [(3,279) d](/filings/0001104659-26-094544.md) |
| Capital expenditure | $k | not reported | [7.2 d](/filings/0001558370-25-003588.md) | [8.0](/filings/0001558370-25-007667.md) | [7.5 d](/filings/0001558370-25-011152.md) | [0.0 d](/filings/0001104659-25-109867.md) | [0.0 d](/filings/0001104659-26-028068.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.7](/filings/0001558370-23-018572.md) | [3.3](/filings/0001558370-24-008069.md) | [3.7](/filings/0001558370-24-011806.md) | [3.7](/filings/0001558370-24-014767.md) | [4.2](/filings/0001558370-25-007667.md) | [5.9](/filings/0001558370-25-011152.md) | [5.9](/filings/0001104659-25-109867.md) | [6.0](/filings/0001104659-26-059743.md) | [6.1](/filings/0001104659-26-094544.md) | [6.4](/filings/0001104659-25-109867.md) | [14.7](/filings/0001104659-26-059743.md) | [53.5](/filings/0001104659-26-094544.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,591,136 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001104659-26-094544.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.